Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

Sanofi invests $30m in MeiraGTx’s gene therapy pipeline

By Jonathan Smith

The London and New York-based gene therapy player MeiraGTx Holdings has received a $30 million investment from Sanofi in addition to potential strategic deals with the big pharma company down the road.


Sanofi to acquire Provention Bio for $2.9bn

By Rachel Arthur

Sanofi will acquire US-based Provention Bio: gaining Tzield (teplizumab-mzwv), which was approved by the FDA last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes.


FDA approves once-weekly hemophilia A therapy

By Rachel Arthur

The US Food and Drug Administration (FDA) has approved Sanofi and Sobi’s Altuviiio (efanesoctocog alfa): a first-in-class, high-sustained factor VIII replacement therapy.

© GettyImages/PM Images

Most popular stories in October 2022

By Jane Byrne

Novo Nordisk, Sanofi, AstraZenec, Merck and Moderna, among others, feature in our round-up of top hitting stories last month.


Positive booster data for Sanofi/GSK COVID-19 vaccine

By Rachel Arthur

A single booster dose of Sanofi and GSK’s recombinant adjuvanted COVID-19 vaccine candidate delivered ‘consistently strong immune responses’, according to data released by the companies.


Sanofi to help manufacture Janssen COVID-19 vaccine

By Rachel Arthur

Sanofi’s vaccine manufacturing plant in Marcy l’Etoile, France, will formulate and fill vials of Janssen’s COVID-19 vaccine: producing around 12 million doses a month to help address global supply demands.


France ramps up COVID-19 vaccine production

By Rachel Arthur

Three COVID-19 vaccine manufacturing sites are set to start production in France in the coming weeks: while the French government is seeking to boost further production with a €300m ($363m) initiative announced on Monday.


Sanofi to acquire Kymab for up to $1.45bn

By Rachel Arthur

Sanofi will acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies. The acquisition will give it global rights to KY1005, which has the potential to treat a range of immune-mediated diseases and inflammatory...